LB Pharmaceuticals Inc
LBRX
$14.90
-$0.61-3.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.09M | -5.09M | -9.63M | -9.63M | -27.70M |
| Total Depreciation and Amortization | 77.50K | 77.50K | 42.50K | 42.50K | 3.00K |
| Total Amortization of Deferred Charges | -- | -- | 1.61M | 1.61M | -- |
| Total Other Non-Cash Items | 157.00K | 157.00K | 548.00K | 548.00K | 2.10M |
| Change in Net Operating Assets | -2.01M | -2.01M | -6.43M | -6.43M | 9.81M |
| Cash from Operations | -6.87M | -6.87M | -13.85M | -13.85M | -15.78M |
| Capital Expenditure | -6.00K | -6.00K | -340.50K | -340.50K | -41.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.50M | 2.50M | 21.55M | 21.55M | 6.93M |
| Cash from Investing | 2.49M | 2.49M | 21.21M | 21.21M | 6.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 10.00K | 10.00K | 3.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Financing | -- | -- | 10.00K | 10.00K | 3.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.37M | -4.37M | 7.37M | 7.37M | -8.89M |